Samsung BioLogics building in Songdo (Park Hyun-koo/The Korea Herald)
TaiMed, a Taiwan-based biotechnology company, has picked Samsung BioLogics as its new contract manufacturing organization for the production of its novel biologic Trogarzo, used to treat patients with multidrug resistant HIV. The multiyear capacity contract, worth 150 billion won ($132 million), was concluded in August last year. Read More
Reading Time: < 1 minute They are the third most commonly used form of contraception in the UK, behind the Pill and the hormonal implant, official data…
Reading Time: < 1 minute An increasing number of people catching the sexually transmitted infection are finding it does not respond to antibiotics. Read More
Reading Time: < 1 minute Sexually transmitted infections (STIs) and reproductive tract infections (RTIs) are major global health issues, impacting quality of life, causing infertility, cancers, and…
Subscribe to our Blog
Let's stay in touch. Subscribe to our blog and get our best content in your inbox.
